title: Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study.
abstract: This article reports further analyses of the Hypertension Optimal Treatment (HOT) Study data with the aim to describe (1) the value of baseline serum creatinine and its clearance (estimated by Cockroft and Gault formula) as predictors of cardiovascular events, (2) the effects of intensive lowering of BP on cardiovascular events and renal function in patients with reduced renal function, and (3) the effects on cardiovascular events of adding acetylsalicylic acid to antihypertensive therapy in patients with reduced renal function. The results show that (1) baseline elevation in serum creatinine and a reduction in estimated creatinine clearance are powerful predictors of cardiovascular events and death. (2) Reduced renal function at baseline did not preclude the desired control of BP. In contrast to patients with normal renal function, the incidence of major cardiovascular events did not differ in the three groups of patients with mild renal insufficiency randomized to different diastolic BP targets. No significant changes in serum creatinine were seen at the end of the 3.8-yr treatment period in the great majority of patients. However, there was a small group of patients (0.58% of the total study population) whose renal function deteriorated (increase > or =30% over baseline and final serum creatinine concentration > or =2 mg/dl) despite satisfactory reduction of diastolic BP. (3) The results of this reanalysis of the HOT Study suggest though do not prove that the association of acetylsalicylic acid with intensive antihypertensive therapy offers additional benefit in hypertensive patients with reduced renal function.
authors.affiliation: Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain.
authors.forename: Luis M
authors.initials: LM
authors.lastname: Ruilope
authors.affiliation: Clinica Medica, University of Pisa, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Salvetti
authors.affiliation: Division of Hypertension, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan.
authors.forename: Kenneth
authors.initials: K
authors.lastname: Jamerson
authors.affiliation: Clinical Hypertension Research, Department of Public Health and Social Sciences, University of Uppsala, Uppsala, Sweden.
authors.forename: Lennart
authors.initials: L
authors.lastname: Hansson
authors.affiliation: AstraZeneca R&D, Mölndal, Sweden.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Warnold
authors.affiliation: Nordic School of Public Health, Göteborg, Sweden.
authors.forename: Hans
authors.initials: H
authors.lastname: Wedel
authors.affiliation: Centro di Fisiologia Clinica e Ipertensione, University of Milan, Ospedale Maggiore di Milano and Instituto Auxologico Italiano, Milan, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Zanchetti
mesh_terms: D000368:Aged; D001241:Aspirin / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D007668:Kidney / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged
chemical_list: D003404:Creatinine; D001241:Aspirin